CoChat

Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial

Gerstein, Hertzel C., Ratner, Robert E., Cannon, Christopher P., Serruys, Patrick W., García-García, Héctor M., van Es, Gerrit-Anne, Kolatkar, Nikheel S., Kravitz, Barbara G., Miller, Diane M., Huang, Chun, Fitzgerald, Peter J., Nesto, Richard W., the APPROACH Study Group · 2010 · Circulation
Cited by 103

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background— Rosiglitazone has several properties that may affect progression of atherosclerosis. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History (APPROACH) study was undertaken to determine the effect of the thiazolidinedione rosiglitazone on coronary atherosclerosis as assessed by intravascular ultrasound compared with the sulfonylurea glipizide. Methods and Results— This was a randomized, double-blind, controlled 18-month study in 672 patients aged 30 to 80 years with established type 2 diabetes mellitus treated by lifestyle, 1 oral agent, or submaximal doses of 2 oral agents who had at least 1 atherosclerotic plaque with 10% to 50% luminal narrowing in a coronary artery that had not undergone intervention during a clinically indicated coronary angiography or percutaneous coronary intervention. The primary outcome was change in percent atheroma volume in the longest and least angulated epicardial coronary artery that had not undergone intervention. Secondary outcomes included change in normalized total atheroma volume and change in total atheroma volume in the most diseased baseline 10-mm segment. Rosiglitazone did not significantly reduce the primary outcome of percent atheroma volume compared with glipizide (−0.64%; 95% confidence interval, −1.46 to 0.17; P =0.12). The secondary outcome of normalized total atheroma volume was significantly reduced by rosiglitazone compared with glipizide (−5.1 mm 3 ; 95% confidence interval, −10.0 to −0.3; P =0.04); however, no significant difference between groups was observed for the change in total atheroma volume within the most diseased baseline 10-mm segment (−1.7 mm 3 ; 95% confidence interval, −3.9 to 0.5; P =0.13). Conclusions— Rosiglitazone did not significantly decrease the primary end point of progression of coronary atherosclerosis more than glipizide in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clinical Trial Registration— http://www.clinicaltrials.gov. Unique Identifier: NCT00116831.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.881003

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 27

  1. 10.1136/bmj.38678.389583.7C · DOI · Paper page
  2. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  3. 10.1016/S0002-8703(03)00239-4 · doi:10.1016/s0002-8703(03)00239-4
  4. 10.1161/01.cir.0000142048.94084.ca · DOI
  5. 10.1001/jama.292.18.2217 · DOI · Paper page
  6. 10.1001/jama.291.9.1071 · DOI · Paper page
  7. 10.1161/01.cir.0000140261.58966.a4 · DOI · Paper page
  8. 10.1161/circ.104.4.387 · doi:10.1161/circ.104.4.387
  9. 10.1016/S0002-9149(97)00221-X · DOI
  10. 10.1161/01.cir.0000025403.20953.23 · DOI · Paper page
  11. 10.2337/diacare.27.6.1349 · DOI · Paper page
  12. 10.1592/phco.25.5.637.63587 · DOI
  13. 10.1177/1358863X07084200 · DOI
  14. 10.1111/j.1524-6175.2005.04784.x · DOI · Paper page
  15. 10.1001/jama.296.21.joc60158 · DOI · Paper page
  16. 10.1016/j.ahj.2007.04.005 · DOI
  17. 10.1001/jama.299.13.1561 · DOI · Paper page
  18. 10.1016/j.ahj.2008.07.025 · DOI
  19. 10.1002/ccd.10693 · DOI
  20. 10.1016/j.amjcard.2007.02.073 · DOI
  21. 10.1016/S0197-2456(99)00022-7 · DOI · Paper page
  22. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007; 153: 445–446.
  23. 10.2337/dc06-1854 · DOI · Paper page
  24. 10.1001/jama.298.10.1189 · DOI · Paper page
  25. 10.1016/S0140-6736(07)61514-1 · DOI · Paper page
  26. 10.1186/1756-0500-2-5 · DOI
  27. Mannucci E Monami M Di Bari M Lamanna C Gori F Gensini GF Marchionni N. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol. Mar 26 2009. DOI: 10.1016/j.ijcard.2009.01.064. Available at: http://www.internationaljournalofcardiology.com/article/S0167-5273%2809%2900133-8/fulltext/. Accessed September 12 2009. · DOI

Cited by

See all 103

Metadata

Authors
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., Fitzgerald, P. J., Nesto, R. W., & the APPROACH Study Group
Venue
Circulation
Published
2010-03-16
Volume
121
Issue
10
Pages
1176-1187
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2135683342
Cited by
103
References
9
FWCI
13.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial. https://app.cochat.ai/papers/10.1161/circulationaha.109.881003
The paper
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W., García-García, H. M., van Es, G.-A., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., Fitzgerald, P. J., Nesto, R. W., & the APPROACH Study Group. (2010). Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History Trial. Circulation. https://doi.org/10.1161/circulationaha.109.881003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.